ArticleJournal of translational medicine2025
ANKHD1 promotes pathogenic proliferation in Autosomal Dominant Polycystic Kidney Disease via the Cyclin D1/CDK4 pathway.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAutosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common genetic cause of renal failure. Uncontrolled proliferation drives ADPKD, which manifests with cystic kidney enlargement. Yet, the mechanisms by which renal epithelial cells lose cell cycle control are largely unknown. To investigate this, we examined the expression and function of the Ankyrin Repeat and single KH Domain 1 (ANKHD1), which positively regulates proliferation in cancer, yet its role in ADPKD is unexplored.
resultsWe report elevated proliferation (Ki67 and Cyclin D1) in three independent mouse models of ADPKD, the Pkd1nl/nl, the Pax8-cre; Pkd1del/del and the KSP-cre; Pkd1del/del. We find that ANKHD1 protein localises in cyst lining cells of both aquaporin-1 and 2 (AQP1-AQP2) positive cysts. ANKHD1 knockdown in human cells or knockout in mouse tissues resulted in reduced proliferation, slower cystic growth in vitro and smaller kidneys in vivo; ultimately leading to improved renal function. Mechanistically, ANKHD1 binds to CDK4 and positively controls the Cyclin D1/CDK4 pathway. ANKHD1-mediated enhancement of Cyclin D1/CDK4 activity leads to increased retinoblastoma phosphorylation and proliferation, a mechanism that is p19-dependent but p21 independent.
conclusionsWe report a functional role for ANKHD1 in driving pathogenic proliferation in ADPKD via the Cyclin D1/CDK4 axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.